# Resolve Therapeutics, LLC

> Resolve Therapeutics is a small, privately held Miami biopharma company developing enzyme-based drugs that clear inflammatory cell-free RNA, DNA and neutrophil extracellular traps from the bloodstream. Its lead biologic, RSLV-132, is being tested in a confirmatory Phase 2 trial for women with Sjögren's disease after earlier studies produced a mixed but intriguing pattern: missed primary endpoints in lupus and long COVID, alongside symptom and subgroup signals that helped the company sharpen whom it treats and what it measures. A second, preclinical candidate, RSLV-145, adds DNase activity for diseases involving NETs, including stroke and other acute inflammatory conditions.

- **Founded:** 2010
- **Headquarters:** Miami, United States
- **Founders:** James Posada, Ph.D. (Founder and Chief Executive Officer)
- **Team size:** Approximately 4 employees, with a wider network of board members, clinical advisers, investigators and academic collaborators
- **Products:** RSLV-132, RSLV-145
- **Notable:** Advanced RSLV-132 from a University of Washington concept to an IND-stage clinical candidate on less than $3 million in early funding, according to the company's 2012 financing announcement., Completed five clinical trials of RSLV-132 and reported a favorable safety profile across those studies., Published randomized clinical results in Sjögren's disease, systemic lupus erythematosus and long COVID in peer-reviewed journals.

## Products & services

- **RSLV-132** — A clinical-stage, fully human RNase1-Fc fusion biologic designed to remain in circulation and digest extracellular pathogenic RNA. It has been studied in lupus, Sjögren's disease and post-acute sequelae of COVID-19; a confirmatory Phase 2 Sjögren's trial is the lead program.
- **RSLV-145** — A preclinical bispecific RNase-DNase Fc fusion designed to digest extracellular RNA, DNA and neutrophil extracellular traps. Resolve is assessing it in autoimmune and acute indications including stroke and subarachnoid hemorrhage.

## Achievements

- Advanced RSLV-132 from a University of Washington concept to an IND-stage clinical candidate on less than $3 million in early funding, according to the company's 2012 financing announcement.
- Completed five clinical trials of RSLV-132 and reported a favorable safety profile across those studies.
- Published randomized clinical results in Sjögren's disease, systemic lupus erythematosus and long COVID in peer-reviewed journals.
- Received US Patent No. 12,077,790 in 2024 for optimized binuclease fusions and methods.
- Opened a multicenter, randomized, double-blind, placebo-controlled confirmatory Phase 2 study of RSLV-132 in women with Sjögren's disease.
- Expanded the platform from chronic autoimmunity into preclinical acute-care work in polytrauma, ischemic stroke and subarachnoid hemorrhage.

## Latest updates

- **2026-04** — Resolve and Institut Pasteur de Montevideo announced a collaboration using REJOIN-seq to identify fragile cell-free RNA triggers in autoimmune disease.
- **2025-11** — The company said it would present its cell-free nucleic-acid platform and clinical progress at the CNAPS symposium in Hong Kong.
- **2025-05** — Resolve and Duke University School of Medicine initiated an observational study of cell-free RNA in polytrauma patients.
- **2024-09** — The US Patent and Trademark Office issued Patent No. 12,077,790 covering optimized binuclease fusions and methods.
- **2024-06** — A confirmatory Phase 2 study of RSLV-132 in women with Sjögren's disease was registered; the record listed recruiting status at its July 2025 update.
- **2024-05** — Peer-reviewed Phase 2 long-COVID results reported no statistically significant difference at day 71 on primary or secondary endpoints, with earlier fatigue signals and larger responses among women.
- **2024-02** — Published lupus Phase 2a results showed no significant improvement on the primary CLASI endpoint, while higher-disease-activity subgroups trended in favor of RSLV-132.

## Links

- Website: https://www.resolvetherapeutics.com/
- LinkedIn: https://www.linkedin.com/company/resolve-therapeutics-llc
- Twitter/X: https://twitter.com/Jimposada
- Facebook: https://facebook.com/ResolveBio

---

Profile page: https://yespress.io/resolve-therapeutics-llc
Published by YesPress — https://yespress.io
Last updated: 2026-08-22